

**BIOCHEMICAL IMPACT OF PHOSPHOLIPID-CONTAINING DRUGS ON LIVER DISEASES:
A COMPREHENSIVE STUDY**

<https://doi.org/10.5281/zenodo.10265103>

Alimov S.M

Tashkent Medical Academy

Abstract: *The biochemical insights into phospholipid-containing drugs provide a promising foundation for the development of novel therapies for liver diseases. Clinically, these drugs hold the potential to not only treat but also prevent the progression of liver conditions. Ongoing research focuses on optimizing drug formulations, dosage, and delivery methods to enhance their efficacy and reduce side effects.*

Keywords: *Liver, cell membranes, fatty, phospholipids, antioxidant.*

INTRODUCTION:

Liver diseases, ranging from fatty liver disease to more severe conditions like cirrhosis, pose a significant global health burden. Researchers and medical professionals have been exploring innovative approaches to tackle these diseases. One promising avenue of study involves understanding the biochemical effects of drugs containing phospholipids on liver health. Phospholipids, crucial components of cell membranes, have shown potential in mitigating liver-related ailments. This article delves into the intricate relationship between phospholipid-containing drugs and liver diseases, exploring the biochemical mechanisms at play.

PHOSPHOLIPIDS: GUARDIANS OF CELL MEMBRANES:

Phospholipids, characterized by their hydrophilic heads and hydrophobic tails, form the structural basis of cell membranes. These molecules not only provide structural integrity to cells but also play a vital role in cellular signaling and transport. In the context of liver diseases, maintaining the integrity of liver cell membranes is paramount for normal liver function.

PHOSPHOLIPIDS AND LIVER HEALTH:

Studies have shown that certain phospholipid-containing drugs exhibit hepatoprotective properties. These drugs enhance the structural integrity of liver cell membranes, preventing oxidative damage and inflammation. Additionally, phospholipids contribute to the regeneration of damaged liver cells, promoting overall liver recovery.

BIOCHEMICAL MECHANISMS:

Phospholipid-containing drugs exert their beneficial effects through various biochemical pathways. One such mechanism involves the modulation of lipid metabolism. By regulating lipid levels in the liver, these drugs prevent the accumulation of harmful fats, reducing the risk of fatty liver disease. Moreover, phospholipids have antioxidant

properties, combating oxidative stress, a significant contributor to liver damage. These drugs also regulate immune responses and inflammatory processes, further safeguarding liver tissues from injury.

REFERENCES:

1. The biochemical effects of phospholipid-containing drugs on liver diseases signify a significant stride in the realm of hepatology. By targeting fundamental cellular components and pathways, these drugs offer new hope for patients battling liver ailments. Continued research and clinical trials are essential to harness the full potential of phospholipid-based interventions, paving the way for improved treatments and ultimately, better outcomes for individuals affected by liver diseases.. – 2018. – Vol. 168, №14. – P. 1568-1575.
2. Abduvaliev A.R., Inoyatova F.Kh., Mirkomilov E.M. A method of inhibiting t-helper 2 cells to prevent lung fibrosis that develops as a result of atypical pneumonia in COVID-19 // Proceeding of Global Congress of Contemporary Study- A Multidisciplinary International Scientific Conference Hosted from Pune, M.S. India.- P.182-187. www.econferenceglobe.com.
3. Sushentseva N. N., Popov O. S., Apalko S. V. et al. Biobank COVID-19: features of the cytokine profile / / Cardiovascular therapy and prevention. 2020, vol.19 (6), pp. 191-195..191-195.
4. Xia H., Bodempudi V., Benyumov A. et al. Identification of a celloforigin for fibroblasts comprising the fibrotic reticulum in idiopathic pulmonary fibrosis Am. J. Pathol. 2014;184: 1369–1383.
5. Maher T.M. Beyond the diagnosis of idiopathic pulmonary fibrosis: the growing role of systems biology and stratified medicine. Curr. Opin. Pulm. Med. 2013; 19: 460–465.
6. Thorax. The pulmonary physician in critical care 6: The pathogenesis of ALI/ARDS/ G.J.Bellingan // Thorax 2002 Jun; 57(6):540-6./ doi:10.1136/ thorax. 57.6.540.
7. Ниёзова, Ш. С., Турсунов, Д. Х., Алимов, С. М., Ахматова, К. А., & Султонова, Д. Ш. (2023). Covid-19 билан касалланган беморлар қон зардобида оқсил алмашинуви кўрсаткичларининг тахлили (Doctoral dissertation, KLINIK LABORATOR DIAGNOSTIKADA INNOVATSION TEXNOLOGIYALARDAN FOYDALANISH, MUAMMOLAR VA YECHIMLAR).